aTyr Pharma (NASDAQ:ATYR) Announces Earnings Results, Misses Estimates By $0.06 EPS

aTyr Pharma (NASDAQ:ATYR) released its earnings results on Thursday. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.06), Zacks reports. The business had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.91 million.

aTyr Pharma Stock Up 6.0%

Shares of ATYR stock traded up $0.05 on Friday, reaching $0.82. 4,496,575 shares of the stock were exchanged, compared to its average volume of 4,944,241. The company has a market capitalization of $80.05 million, a price-to-earnings ratio of -1.02 and a beta of 0.81. The business’s 50 day moving average price is $1.84 and its 200 day moving average price is $3.74. The company has a current ratio of 5.63, a quick ratio of 5.63 and a debt-to-equity ratio of 0.01. aTyr Pharma has a twelve month low of $0.68 and a twelve month high of $7.29.

Insider Transactions at aTyr Pharma

In other aTyr Pharma news, Director Paul Schimmel acquired 317,999 shares of the stock in a transaction dated Thursday, October 9th. The stock was acquired at an average cost of $0.94 per share, with a total value of $298,919.06. Following the transaction, the director owned 1,413,023 shares in the company, valued at $1,328,241.62. The trade was a 29.04% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On aTyr Pharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Millennium Management LLC increased its position in aTyr Pharma by 334.5% in the 1st quarter. Millennium Management LLC now owns 1,599,041 shares of the company’s stock valued at $4,829,000 after acquiring an additional 1,231,052 shares during the period. Vanguard Group Inc. grew its stake in shares of aTyr Pharma by 21.0% in the 3rd quarter. Vanguard Group Inc. now owns 5,630,935 shares of the company’s stock valued at $4,060,000 after purchasing an additional 975,887 shares during the last quarter. Invesco Ltd. acquired a new position in shares of aTyr Pharma in the second quarter valued at approximately $3,032,000. Octagon Capital Advisors LP raised its stake in shares of aTyr Pharma by 7.5% during the second quarter. Octagon Capital Advisors LP now owns 3,820,000 shares of the company’s stock worth $19,367,000 after purchasing an additional 268,000 shares during the last quarter. Finally, Rhumbline Advisers purchased a new stake in shares of aTyr Pharma during the second quarter worth approximately $629,000. 61.72% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. Jones Trading lowered shares of aTyr Pharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 15th. Cantor Fitzgerald cut shares of aTyr Pharma from an “overweight” rating to a “neutral” rating in a research report on Monday, September 15th. Leerink Partnrs downgraded shares of aTyr Pharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of aTyr Pharma in a research note on Wednesday, October 8th. Finally, Leerink Partners reissued a “market perform” rating on shares of aTyr Pharma in a research note on Monday, September 15th. One equities research analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $23.25.

About aTyr Pharma

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.